Assessment of the endocrine disrupting properties of bisphenol AF: a case study applying the European regulatory criteria and guidance.

Bisphenol AF Endocrine disruptors Pesticides regulation REACH Risk assessment Weight of evidence evaluation

Journal

Environmental health : a global access science source
ISSN: 1476-069X
Titre abrégé: Environ Health
Pays: England
ID NLM: 101147645

Informations de publication

Date de publication:
24 04 2021
Historique:
received: 06 10 2020
accepted: 15 04 2021
entrez: 25 4 2021
pubmed: 26 4 2021
medline: 19 8 2021
Statut: epublish

Résumé

Scientific criteria to identify endocrine disruptors (ED) was recently implemented for plant protection products (PPP) and biocidal products (BP). A guidance document has been published by ECHA and EFSA in the context of ED criteria for PPPs and BPs. In the present work, a case study was performed on Bisphenol AF (BPAF) to explore the application of the EU criteria and EFSA/ECHA guidance document for the ED assessment of a non-pesticide chemical regulated under REACH. A data dossier was built by a systematic literature search (Web of Science, Pubmed, Embase; n = 511), title/abstract screening (n = 124) and full text examination (n = 88). All the information was extracted and systematically reported for 309 parameters (100 for adversity; 209 for endocrine activity). The reliability of studies was assessed (SciRAP tool). Data were synthesized into 96 lines of evidence for adversity (n = 57), and endocrine activity (n = 39); and assessed by weight of evidence methodology. The initial analysis of the evidence indicated EATS-mediated adversity in mammals, therefore a mode of action (MoA) was postulated for both male and female adult exposure. Female MoA included estrogen receptor activation and altered steroidogenesis leading to ovarian dysfunction, altered estrous cycling and impaired female fertility. Male MoA was initiated by androgen receptor inhibition and altered steroidogenesis leading to dysfunction of male reproductive organs and impaired male fertility. The overall conclusion of the ED assessment indicated that BPAF meets the ED criteria for human health. The steps described in the ED guidance document were successfully completed, resulting in a thorough, structured and transparent identification of BPAF as an ED. Advantages and limitations of applying the ED criteria and guidance for a REACH chemical are discussed.

Sections du résumé

BACKGROUND
Scientific criteria to identify endocrine disruptors (ED) was recently implemented for plant protection products (PPP) and biocidal products (BP). A guidance document has been published by ECHA and EFSA in the context of ED criteria for PPPs and BPs.
METHODS
In the present work, a case study was performed on Bisphenol AF (BPAF) to explore the application of the EU criteria and EFSA/ECHA guidance document for the ED assessment of a non-pesticide chemical regulated under REACH. A data dossier was built by a systematic literature search (Web of Science, Pubmed, Embase; n = 511), title/abstract screening (n = 124) and full text examination (n = 88). All the information was extracted and systematically reported for 309 parameters (100 for adversity; 209 for endocrine activity). The reliability of studies was assessed (SciRAP tool).
RESULTS
Data were synthesized into 96 lines of evidence for adversity (n = 57), and endocrine activity (n = 39); and assessed by weight of evidence methodology. The initial analysis of the evidence indicated EATS-mediated adversity in mammals, therefore a mode of action (MoA) was postulated for both male and female adult exposure. Female MoA included estrogen receptor activation and altered steroidogenesis leading to ovarian dysfunction, altered estrous cycling and impaired female fertility. Male MoA was initiated by androgen receptor inhibition and altered steroidogenesis leading to dysfunction of male reproductive organs and impaired male fertility.
CONCLUSIONS
The overall conclusion of the ED assessment indicated that BPAF meets the ED criteria for human health. The steps described in the ED guidance document were successfully completed, resulting in a thorough, structured and transparent identification of BPAF as an ED. Advantages and limitations of applying the ED criteria and guidance for a REACH chemical are discussed.

Identifiants

pubmed: 33894771
doi: 10.1186/s12940-021-00731-0
pii: 10.1186/s12940-021-00731-0
pmc: PMC8070297
doi:

Substances chimiques

Benzhydryl Compounds 0
Endocrine Disruptors 0
Phenols 0
4,4'-hexafluorisopropylidene diphenol OH7IX8A37J

Banques de données

figshare
['10.6084/m9.figshare.14479934.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

48

Références

Environ Int. 2020 Sep;142:105828
pubmed: 32502797
Environ Health. 2016 Jul 14;15(1):74
pubmed: 27412149
EFSA J. 2019 Jul 08;17(Suppl 1):e170711
pubmed: 32626448
Mol Cell Endocrinol. 2018 Nov 5;475:4-9
pubmed: 29426018
J Appl Toxicol. 2014 Jun;34(6):607-17
pubmed: 24481642
J Appl Toxicol. 2018 Dec;38(12):1460-1470
pubmed: 29806706
Chemosphere. 2016 Sep;158:131-42
pubmed: 27262103
Environ Sci Technol. 2016 Jun 7;50(11):5438-53
pubmed: 27143250
Environ Health Perspect. 2014 Oct;122(10):1007-14
pubmed: 24968373
EFSA J. 2018 Jun 07;16(6):e05311
pubmed: 32625944
Environ Toxicol Pharmacol. 2016 Oct;47:182-199
pubmed: 27771500
Regul Toxicol Pharmacol. 1997 Feb;25(1):1-5
pubmed: 9056496
Front Neuroendocrinol. 2017 Oct;47:123-133
pubmed: 28801100
Crit Rev Toxicol. 2020 Feb;50(2):128-147
pubmed: 32031044
Mol Endocrinol. 2016 Aug;30(8):833-47
pubmed: 27477640
Environ Health Perspect. 2014 Jul;122(7):711-8
pubmed: 24755067
EFSA J. 2017 Aug 03;15(8):e04971
pubmed: 32625632
Environ Int. 2020 Nov;144:105996
pubmed: 32771829
Environ Int. 2016 Jul-Aug;92-93:556-64
pubmed: 26687863

Auteurs

Laura Escrivá (L)

Faculty of Pharmacy, University of Valencia, Burjassot, Valencia, Spain. laura.escriva@uv.es.

Johanna Zilliacus (J)

Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden.

Ellen Hessel (E)

RIVM National Institute for Public Health and the Environment, Utrecht, The Netherlands.

Anna Beronius (A)

Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH